The facility (which is close to the scientific park and the university) will have dedicated space for production, services, and drug discovery/R&D. The new building will be renewed and ready in Q2-2022. Immagina developed a platform technology dedicated to unlocking the therapeutic potential of ribosomes. Immagina integrates cutting-edge technologies in sequencing, computational biology, and cellular and molecular biology to provide an understanding of ribosome biology that will lead to transformational therapeutics that improve human health. The basic version of Immagina's technologies are on the market and commercially available. Immagina is now one of the world's most valuable companies in the RNA space, and is also approaching an impacting round of investment "What makes this round special is that it’s led by the people who know us best” said Massimiliano Clamer, founder and President of Immagina.